Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Ultrastruct Pathol ; 48(3): 234-245, 2024 May 03.
Article in English | MEDLINE | ID: mdl-38619195

ABSTRACT

Platelet-viral interactions are evolving as a new concern. Coagulation disorder is a major consequence of the COVID-19 infection. In chronic hepatitis virus infections, defect in coagulation factors, thrombocytopenia and platelet function abnormalities are common. A SARS-CoV-2 infection on top of chronic viral hepatitis infection can be common in areas where viral hepatitis is endemic. Here, we investigate the platelet ultrastructural changes and estimate the serum platelet factor-4 (PF-4), ferritin, CRP, and D-dimer in COVID-19 patients (n = 60), COVID-19 patients with associated chronic viral hepatitis (n = 20), and healthy subjects (n = 20). Ultrastructural changes were demonstrated in all test groups, denoting platelet activation. In chronic viral hepatitis patients, Platelet ultrastrustural apoptotic changes were also seen. Significantly high levels of PF-4 were confirmed in moderate and severe COVID-19 patients (P.value <0.001), with a cut off value of 17 ng/ml for predicting disease severity. A positive correlation of PF-4 with the level of serum ferritin, CRP, and D-dimer (p value < 0.001) was noted, while negatively correlated with platelet count and platelet granule count (p value < 0.001). In our study, chronic viral hepatitis patients presented mild COVID-19 signs, and their PF-4 level was comparable with the subgroup of mild COVID-19 infection. The platelet's critical role in COVID-19 coagulopathy and chronic viral hepatitis is evidenced by the ultrastructural changes and the high levels of PF4. Moreover, a dual viral infection poses a substantial burden on the platelets, necessitating close monitoring of the patient's coagulation profile.


Subject(s)
Blood Platelets , COVID-19 , Humans , COVID-19/complications , COVID-19/blood , COVID-19/pathology , Blood Platelets/ultrastructure , Male , Female , Middle Aged , Adult , SARS-CoV-2 , Fibrin Fibrinogen Degradation Products/analysis , Platelet Count , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/blood , Hepatitis C, Chronic/pathology , Aged , Platelet Factor 4/blood , Platelet Activation
3.
Sci Rep ; 6: 21005, 2016 Feb 15.
Article in English | MEDLINE | ID: mdl-26876222

ABSTRACT

Liver fibrosis is one of the most serious consequences of S. mansoni infection. The aim of the present study was to investigate the potential anti-fibrotic effect of human Wharton's jelly-derived mesenchymal stem cells (WJMSCs) combined with praziquantel (PZQ) in S. mansoni-infected mice. S. mansoni-infected mice received early (8(th) week post infection) and late (16(th) week post infection) treatment with WJMSCs, alone and combined with oral PZQ. At the 10(th) month post infection, livers were collected for subsequent flow cytometric, histopathological, morphometric, immunohistochemical, gene expression, and gelatin zymographic studies. After transplantation, WJMSCs differentiated into functioning liver-like cells as evidenced by their ability to express human hepatocyte-specific markers. Regression of S. mansoni-induced liver fibrosis was also observed in transplanted groups, as evidenced by histopathological, morphometric, and gelatin zymographic results besides decreased expression of three essential contributors to liver fibrosis in this particular model; alpha smooth muscle actin, collagen-I, and interleukin-13. PZQ additionally enhanced the beneficial effects observed in WJMSCs-treated groups. Our results suggest that combining WJMSCs to PZQ caused better enhancement in S. mansoni-induced liver fibrosis, compared to using each alone.


Subject(s)
Liver Cirrhosis/therapy , Mesenchymal Stem Cell Transplantation , Schistosomiasis mansoni/therapy , Wharton Jelly/transplantation , Animals , Cell- and Tissue-Based Therapy , Humans , Liver Cirrhosis/parasitology , Liver Cirrhosis/pathology , Mesenchymal Stem Cells/cytology , Mice , Praziquantel/administration & dosage , Schistosoma mansoni/drug effects , Schistosoma mansoni/pathogenicity , Schistosomiasis mansoni/parasitology , Schistosomiasis mansoni/pathology , Wharton Jelly/cytology
4.
APMIS ; 119(1): 66-75, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21143528

ABSTRACT

The in vivo angiogenic potential of transplanted human umbilical cord blood (UCB) CD133(+) stem cells in experimental chronic hepatic fibrosis induced by murine schistosomiasis was studied. Enriched cord blood-derived CD133(+) cells were cultured in primary medium for 3 weeks. Twenty-two weeks post-Schistosomiasis infection in mice, after reaching the chronic hepatic fibrotic stage, transplantation of stem cells was performed and mice were sacrificed 3 weeks later. Histopathology and electron microscopy showed an increase in newly formed blood vessels and a decrease in the fibrosis known for this stage of the disease. By immunohistochemical analysis the newly formed blood vessels showed positive expression of the human-specific angiogenic markers CD31, CD34 and von Willebrand factor. Few hepatocyte-like polygonal cells showed positive expression of human vascular endothelial growth factor and inducible nitric oxide synthase. The transplanted CD133(+) human stem cells primarily enhanced hepatic angiogenesis and neovascularization and contributed to repair in a paracrine manner by creating a permissive environment that enabled proliferation and survival of damaged cells rather than by direct differentiation to hepatocytes. A dual advantage of CD133(+) cell therapy in hepatic disease is suggested based on its capability of hematopoietic and endothelial differentiation.


Subject(s)
Antigens, CD/blood , Fetal Blood/physiology , Glycoproteins/blood , Liver Cirrhosis/immunology , Neovascularization, Physiologic/physiology , Peptides/blood , Stem Cells/physiology , AC133 Antigen , Adult , Animals , Antigens, CD/immunology , Female , Fetal Blood/cytology , Fetal Blood/immunology , Glycoproteins/immunology , Humans , Immunohistochemistry , Infant, Newborn , Liver Cirrhosis/blood , Mice , Microscopy, Electron , Neovascularization, Physiologic/immunology , Peptides/immunology , Stem Cell Transplantation , Stem Cells/cytology , Stem Cells/immunology , Young Adult
5.
APMIS ; 118(4): 277-87, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20402673

ABSTRACT

The efficiency of differentiation of bone marrow cells (BMCs) into hepatocytes in vivo and its importance in physiopathological processes is still debated. Murine schistosomiasis was used as a liver injury model and unfractionated male mice BMCs were transplanted through intrahepatic injection into non-irradiated Schistosoma mansoni-infected female mice on their 16th week post-infection. Two weeks after bone marrow transplantation, mice were sacrificed on a weekly basis until 10 weeks. Tracing of male donor-derived cells in female recipient mice livers was carried out by the detection of Y chromosome expression by fluorescent in situ hybridization (FISH) and also of chromodomain Y-linked (CDYL) protein by indirect immunofluorescence (IF). Their transformation into hepatocytes was studied by double labelling indirect IF using antibodies directed against CDYL and mouse albumin. Histopathological and electron microscopic examinations revealed the presence of small hepatocyte-like cells in the periportal tracts and in between the hepatocytes facing the sinusoids. Donor-derived cells showing Y chromosome by FISH and expressing CDYL protein by IF were recovered in the infected transplanted livers. The initial number of these cells increased with increased post-transplantation time. Cells were mainly localized in the periphery of schistosoma granuloma. Few donor-derived cells appeared within the hepatic parenchymal tissue and showed positivity for albumin secretion by double labelling with IF. We suggest that transplanted bone marrow stem cells can repopulate the Schistosoma-infected liver of immunocompetent mice. Their differentiation is a complex event controlled by many factors and needs to be further characterized extensively. The extent and type of liver injury and the number of transplanted cells are important variables in the process of stem cell engraftment and differentiation into functioning hepatic cells that still need to be defined.


Subject(s)
Bone Marrow Transplantation , Cell Movement/physiology , Hematopoietic Stem Cells/cytology , Liver/cytology , Schistosomiasis mansoni/surgery , Animals , Female , Fluorescent Antibody Technique , In Situ Hybridization, Fluorescence , Male , Mice
6.
Ultrastruct Pathol ; 34(2): 62-7, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20192701

ABSTRACT

An ultrastructural quantitative assessment of hepatic stellate cells (HSCs) was made in relation to hepatic fibrosis, apoptotic cellular changes, intracellular fat deposition, circulating inflammatory cells in the sinusoids, and the necroinflammatory activity in liver specimens of 33 patients proven to be positive for hepatitis C virus (HCV)-RNA by polymerase chain reaction with the intention that electron microscopy may throw more light on the role of HSCs in the complicated process of fibrogenesis. A detailed review concerning these parameters and observed evidence suggesting the potential properties of HSCs to recycle cellular debris into collagen fibers are reported.


Subject(s)
Hepatic Stellate Cells/ultrastructure , Hepatitis C, Chronic/pathology , Liver Cirrhosis/pathology , Microscopy, Electron, Transmission/methods , Apoptosis/physiology , Hepacivirus/genetics , Hepacivirus/immunology , Hepacivirus/isolation & purification , Hepatic Stellate Cells/chemistry , Hepatitis C, Chronic/metabolism , Humans , Lipids/analysis , Liver Cirrhosis/metabolism , RNA, Viral/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...